73 | PRIMARY ENDPOINT EVALUATION OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH R‐CHOP (VR‐CHOP) FOR PATIENTS WITH RICHTER SYNDROME
Matthew S. Davids(Dana-Farber Cancer Institute), Kathleen A. Rogers(The Ohio State University), Jennifer R. Brown(Dana-Farber Cancer Institute), Josie Montegaard(Dana-Farber Cancer Institute), Nitin Jain(Parul University), R. Merryman(Dana-Farber Cancer Institute), Alexander Kim(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Erin M. Parry(Broad Institute), Inhye E. Ahn(Dana-Farber Cancer Institute), Christine E. Ryan(Dana-Farber Cancer Institute), Philip A. Thompson(The Royal Melbourne Hospital), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Yusen Zhou(Dana-Farber Cancer Institute), Chris Carey(University of Brighton), M. Kniezewski(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University)
Cited by 0
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890